STO · GETI-B.ST
Getinge AB (publ)
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
Loading market information…
STO · ASKER.ST · SEK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Asker Healthcare Group AB’s quoted price sits in the lower half of its reported 52-week range, 25.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Asker Healthcare Group AB’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of SEK 0.56. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Asker Healthcare Group AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion supplies, and wound dressings, alongside advanced medical apparatus like endoscopy systems, incubators, and ventilators. They also distribute pharmaceuticals and offer diagnostic instruments for conditions including diabetes and hypertension. The company equips operating rooms, polyclinics, and day surgery facilities with specialized medical devices, and provides veterinary equipment, hygiene solutions, and targeted products for urology, ultrasound diagnostics, laser treatment, and regenerative medicine. Additionally, their offerings include defibrillators, advanced wound care products, and critical protection and trauma supplies for emergency services, law enforcement, and military personnel, as well as products for beauty clinics. Beyond their core product range, Asker Healthcare Group develops and markets proprietary disposable medical items under the Evercare, Selefa, and Embra brands, and serves as a key distributor of ophthalmic surgical products. They also create and sell innovative solutions for time management, communication, and cognitive support, aimed at schools, assistive technology centers, and various public services. The group extends its offerings to a variety of patient support services, including specialized assistance for wound, diabetes, and urological care, in addition to ostomy, urology, and rehabilitation programs. They supply products for physiotherapy practices, provide exercise and treatment equipment, and offer both sales and rentals of mobility aids and rehabilitation devices, including pressure-relieving mattresses and cushions, which they also manufacture and distribute. Ambulance services are another facet of their diverse operations. Founded in 2018 and headquartered in Danderyd, Sweden, Asker Healthcare Group AB maintains an extensive operational presence across numerous European countries, specifically Sweden, Norway, Finland, Estonia, Latvia, Lithuania, the Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, the Czech Republic, and Poland.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | SEK 0.51-20.31% vs estimate | SEK 4.00B+3.2% vs estimate |
|---|
| Q4 2024 | Mar 31, 2024 | SEK 0.17 | SEK 3.46B |
|---|
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 58.50-SEK 1.00 (-1.68%)
Elekta AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 12.29% below the high.
SEK 320.80+SEK 2.00 (+0.63%)
Bonesupport Holding AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.7% below the high.
SEK 114.40+SEK 1.50 (+1.33%)
Vitrolife AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 24.98% below the high.
SEK 204.20-SEK 0.60 (-0.29%)
Xvivo Perfusion AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 35.13% below the high.
SEK 250.00SEK 0.00 (0.0%)
Stille AB’s quoted price sits in the upper half of its reported 52-week range, 11.66% below the high.
SEK 24.15-SEK 0.10 (-0.41%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
SEK 9.22+SEK 0.23 (+2.56%)
Sedana Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 33.76% below the high.
